Cardio Pulmonary Articles & Analysis
9 news found
Her leadership and extensive drug development experience at Amgen, Merck, and Greenfire Bio aligns with the company’s drug discovery interests across multiple therapeutic areas, including cardio-metabolic, pulmonary, inflammatory ophthalmology, renal and fibrotic diseases. ...
Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator. ...
No identifiable prior medical treatment; Impossibility for the patient to participate in prolonged medical follow-up; Unstable psychotic disorders, severe depressive syndromes that have not been stabilized with a specific treatment, suicidal tendencies; Alcoholism or drug addiction; Severe eating disorders (such as bulimia); An insufficient mastication coefficient; Documented ...
eNOfit™, Third Pole’s novel nitric oxide mobile-wearable device designed to provide “on-the-go” treatment for patients suffering from severe COPD and ILD, to enter clinical trials in the second half of this year Funding will support device optimization and clinical trials; Pivotal trial data expected in the second half of 2023 Third Pole Therapeutics, a privately ...
Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today that it is presenting at the H.C. ...
Third Pole Therapeutics, a privately held company developing and delivering transformative life-saving cardio-pulmonary therapies, announced today its Chief Executive Officer Bill Athenson will present at Biotech Showcase 2020 to be held January 13-15, 2020 at the Hilton San Francisco Union Square. ...
Third Pole Therapeutics, a privately held company developing and delivering transformative life-saving cardio-pulmonary therapies, has named seasoned healthcare executive Bill Athenson as its new Chief Executive Officer, the company announced today. ...
Third Pole Therapeutics, a privately held company developing and delivering transformative life-saving cardio-pulmonary therapies, announced today that the U.S. Patent and Trademark Office has recently issued U.S. patents covering Third Pole’s innovative general and portable inhaled Nitric Oxide (iNO) delivery systems as follows: US Patent No. 10,286.176 ...
Third Pole Therapeutics, a privately held company developing and delivering transformative cardio-pulmonary therapies, announced today that it has entered into a strategic collaboration to work with Actelion Pharmaceuticals Ltd, a Janssen pharmaceutical company of Johnson & Johnson. ...